FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063764520> ?p ?o ?g. }

• W2063764520 endingPage "207" @default.
• W2063764520 startingPage "199" @default.
• W2063764520 abstract "<b><i>Background:</i></b> Pirfenidone is a novel antifibrotic drug for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF). However, adverse events may offset treatment benefits and compliance. <b><i>Objectives:</i></b> To assess recent course of disease, adverse events and compliance in patients who started pirfenidone. <b><i>Methods:</i></b> In an observational cohort study, 63 patients with mild-to-moderate IPF who started pirfenidone between May 2011 and June 2013 were reviewed. Pulmonary function, adverse events and treatment compliance were recorded at each clinic visit. Disease progression was defined as a reduction of vital capacity ≥10% and/or diffusion capacity (DLCO) ≥15%. <b><i>Results:</i></b> Follow-up time on pirfenidone treatment was 11 (±7) months. Sixty-six percent of the patients continued with pirfenidone monotherapy and 34% of the patients received pirfenidone combined with corticosteroids (CCS) and/or N-acetylcysteine (NAC). There was a nonsignificant reduction in mean decline of percent predicted forced vital capacity after treatment start (0.7 ± 10.9%) compared to the pretreatment period (6.6 ± 6.7%, p = 0.098). Sixty-two percent of the patients had stable disease on pirfenidone treatment. Adverse events affected 85% of the patients, leading to discontinuation of pirfenidone in 20%. Adverse events and treatment discontinuation were seen more frequently in patients with concomitant CCS and/or NAC treatment. <b><i>Conclusions:</i></b> Adverse events affect the majority of patients treated with pirfenidone, but are mostly manageable with supportive measures. In this heterogeneous patient group, a nonsignificant effect of pirfenidone treatment on pulmonary function was seen, underlining the need for more data on patient selection criteria and efficacy of pirfenidone, particularly in patients with coexistent emphysema and concomitant NAC/CCS treatment." @default.
• W2063764520 created "2016-06-24" @default.
• W2063764520 creator A5006969715 @default.
• W2063764520 creator A5016216382 @default.
• W2063764520 creator A5020173096 @default.
• W2063764520 creator A5020764249 @default.
• W2063764520 creator A5033500741 @default.
• W2063764520 creator A5064807273 @default.
• W2063764520 creator A5065509965 @default.
• W2063764520 creator A5071404281 @default.
• W2063764520 creator A5071427362 @default.
• W2063764520 creator A5073313731 @default.
• W2063764520 creator A5074182341 @default.
• W2063764520 creator A5074397120 @default.
• W2063764520 creator A5088799541 @default.
• W2063764520 date "2014-01-01" @default.
• W2063764520 modified "2023-10-11" @default.
• W2063764520 title "Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-Life Experience from a German Tertiary Referral Center for Interstitial Lung Diseases" @default.
• W2063764520 cites W1515908253 @default.
• W2063764520 cites W1964124382 @default.
• W2063764520 cites W1975769752 @default.
• W2063764520 cites W1989622233 @default.
• W2063764520 cites W1990240660 @default.
• W2063764520 cites W2004082930 @default.
• W2063764520 cites W2008423420 @default.
• W2063764520 cites W2039127564 @default.
• W2063764520 cites W2057292199 @default.
• W2063764520 cites W2076914293 @default.
• W2063764520 cites W2080677332 @default.
• W2063764520 cites W2084638872 @default.
• W2063764520 cites W2117488044 @default.
• W2063764520 cites W2117618518 @default.
• W2063764520 cites W2130744567 @default.
• W2063764520 cites W2134215992 @default.
• W2063764520 cites W2134956122 @default.
• W2063764520 cites W2135863640 @default.
• W2063764520 cites W2141623508 @default.
• W2063764520 cites W2142941142 @default.
• W2063764520 cites W2149917976 @default.
• W2063764520 cites W2149987257 @default.
• W2063764520 cites W2163147529 @default.
• W2063764520 cites W2163563134 @default.
• W2063764520 cites W2167383172 @default.
• W2063764520 cites W2257076519 @default.
• W2063764520 cites W2626588662 @default.
• W2063764520 cites W64977307 @default.
• W2063764520 doi "https://doi.org/10.1159/000363064" @default.
• W2063764520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25115833" @default.
• W2063764520 hasPublicationYear "2014" @default.
• W2063764520 type Work @default.
• W2063764520 sameAs 2063764520 @default.
• W2063764520 citedByCount "86" @default.
• W2063764520 countsByYear W20637645202014 @default.
• W2063764520 countsByYear W20637645202015 @default.
• W2063764520 countsByYear W20637645202016 @default.
• W2063764520 countsByYear W20637645202017 @default.
• W2063764520 countsByYear W20637645202018 @default.
• W2063764520 countsByYear W20637645202019 @default.
• W2063764520 countsByYear W20637645202020 @default.
• W2063764520 countsByYear W20637645202021 @default.
• W2063764520 countsByYear W20637645202022 @default.
• W2063764520 countsByYear W20637645202023 @default.
• W2063764520 crossrefType "journal-article" @default.
• W2063764520 hasAuthorship W2063764520A5006969715 @default.
• W2063764520 hasAuthorship W2063764520A5016216382 @default.
• W2063764520 hasAuthorship W2063764520A5020173096 @default.
• W2063764520 hasAuthorship W2063764520A5020764249 @default.
• W2063764520 hasAuthorship W2063764520A5033500741 @default.
• W2063764520 hasAuthorship W2063764520A5064807273 @default.
• W2063764520 hasAuthorship W2063764520A5065509965 @default.
• W2063764520 hasAuthorship W2063764520A5071404281 @default.
• W2063764520 hasAuthorship W2063764520A5071427362 @default.
• W2063764520 hasAuthorship W2063764520A5073313731 @default.
• W2063764520 hasAuthorship W2063764520A5074182341 @default.
• W2063764520 hasAuthorship W2063764520A5074397120 @default.
• W2063764520 hasAuthorship W2063764520A5088799541 @default.
• W2063764520 hasBestOaLocation W20637645201 @default.
• W2063764520 hasConcept C126322002 @default.
• W2063764520 hasConcept C141071460 @default.
• W2063764520 hasConcept C16020263 @default.
• W2063764520 hasConcept C165637977 @default.
• W2063764520 hasConcept C197934379 @default.
• W2063764520 hasConcept C2777543607 @default.
• W2063764520 hasConcept C2777714996 @default.
• W2063764520 hasConcept C2778341716 @default.
• W2063764520 hasConcept C2778715236 @default.
• W2063764520 hasConcept C2779832356 @default.
• W2063764520 hasConcept C2780559512 @default.
• W2063764520 hasConcept C2781244666 @default.
• W2063764520 hasConcept C3018587741 @default.
• W2063764520 hasConcept C55520419 @default.
• W2063764520 hasConcept C71924100 @default.
• W2063764520 hasConcept C75603125 @default.
• W2063764520 hasConcept C90924648 @default.
• W2063764520 hasConceptScore W2063764520C126322002 @default.
• W2063764520 hasConceptScore W2063764520C141071460 @default.
• W2063764520 hasConceptScore W2063764520C16020263 @default.
• W2063764520 hasConceptScore W2063764520C165637977 @default.

• next